Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Japan responds: stem-cell therapy justified

  1. Shinji Miyamoto

    1. Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.

    View author publications

    You can also search for this author in PubMed  Google Scholar

As director-general of the Pharmaceutical Safety and Environmental Health Bureau of Japan’s Ministry of Health, Labour and Welfare, I cannot accept your criticism of our approval of stem-cell treatment for spinal-cord injuries (see Nature 565, 535–536; 2019 and Nature 565, 544–545; 2019).

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 569, 40 (2019)

doi: https://doi.org/10.1038/d41586-019-01364-7

Competing Interests

S.M. is employed by Japan’s Ministry of Health, Labour and Welfare, which administers the country’s approval system for regenerative-medicine products.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links